COLUMBIA, Md., Jan 12, 2006 /PRNewswire-FirstCall via COMTEX/ -- Martek Biosciences Corporation (MATK) announced today that infant formula company Medici Medical Ltd. has signed a license agreement for use of Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA) in infant formula sold in Israel.
The omega-3 fatty acid DHA and the omega-6 fatty acid ARA are naturally present in breast milk. Clinical studies have demonstrated cognitive and visual benefits for those infants receiving DHA and ARA supplemented formula.
Martek's proprietary blend of DHA and ARA is the only source of these nutrients that the FDA has cleared for use in U.S. infant formula, and is currently being sold by the Company's licensees in supplemented formulas in over 60 countries around the world.
"The Medici Medical agreement is yet another example of how formula manufacturers are recognizing the benefits of adding Martek's DHA and ARA to formula, both for their business and the infants they serve. It is heartening to know that with every new license agreement, more and more infants around the world will benefit from Martek's DHA and ARA," said Henry "Pete" Linsert, Jr., Chairman and CEO of Martek Biosciences Corporation.
Martek Biosciences Corporation (MATK) develops, manufactures and sells naturally produced products from microalgae and fungi. The Company's products include: (1) specialty, nutritional oils for infant formula that aid in the development of the eyes and central nervous system in newborns; (2) nutritional supplements and food ingredients that may play a beneficial role in promoting mental and cardiovascular health throughout life; and (3) powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection. For more information on Martek Biosciences, visit http://www.martekbio.com.
This press release contains forward-looking statements regarding the commercialization of Martek's products. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors, including without limitation those factors set forth in Martek's filings with the Securities and Exchange Commission.